These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7270207)

  • 1. [Pharmacokinetic tests with delayed-absorption Halidor-Eudragit L complex in dogs].
    Elekes I; Auer P; Pátfalusi M; Orbán E
    Acta Pharm Hung; 1981 Mar; 51(2):66-9. PubMed ID: 7270207
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissolution behaviour of sustained release formulations of indomethacin with Eudragit RS.
    Khanfar MS; Salem MS; Najib NM; Pillai GK
    Acta Pharm Hung; 1997 Nov; 67(6):235-9. PubMed ID: 9423295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolism of benzyclane [1-benzyl-1-(3-N,N-dimethylaminopropoxy)cycloheptane] in rat and man.
    Kimura K; Nagata A; Miyawaki H
    Xenobiotica; 1979 Feb; 9(2):119-27. PubMed ID: 433310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eudragit matrices for sustained release of ketorolac tromethamine: formulation and kinetics of release.
    Ruckmani K; Muneera MS; Vijaya R
    Boll Chim Farm; 2000; 139(5):205-8. PubMed ID: 11213438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100-55 as potential carriers for oral controlled drug delivery.
    Moustafine RI; Margulis EB; Sibgatullina LF; Kemenova VA; Van den Mooter G
    Eur J Pharm Biopharm; 2008 Sep; 70(1):215-25. PubMed ID: 18691856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of aqueous Eudragit dispersions to the preparation of controlled release oral antihistamine dosage forms].
    Dévay A; Rácz I
    Acta Pharm Hung; 1988 Jul; 58(4):166-72. PubMed ID: 2906204
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of 4 formulation factors on the release of indomethacin from inert matrices with a Eudragit base].
    Gueurten D
    Pharm Acta Helv; 1984; 59(7):200-4. PubMed ID: 6473479
    [No Abstract]   [Full Text] [Related]  

  • 8. The attempts of retarding the release of nitroglycerin from granules.
    Stozek T
    Pol J Pharmacol Pharm; 1977; 29(4):425-9. PubMed ID: 410011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
    Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
    Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permeability and swelling studies on free films containing inulin in combination with different polymethacrylates aimed for colonic drug delivery.
    Akhgari A; Farahmand F; Afrasiabi Garekani H; Sadeghi F; Vandamme TF
    Eur J Pharm Sci; 2006 Jul; 28(4):307-14. PubMed ID: 16713201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gas-liquid chromatographic evaluation of bencyclane in biological samples for pharmacokinetic and bioavailability investigations: comparison of two analytical methods.
    Marzo A; Treffner E; Quadro G; Rapelli S
    J Chromatogr; 1985 Sep; 343(1):77-84. PubMed ID: 4066863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacodynamics of compound danshen pH-dependent delayed release pellets in dogs].
    Yang DL; Yu YL; Tang X; Wan HJ; Song HT
    Yao Xue Xue Bao; 2005 Dec; 40(12):1075-9. PubMed ID: 16496668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on heart-protecting musk pH-dependent gradient-release pellets].
    Song HT; Guo T; Zhang RH; Ma Y; Li X; Bi KS
    Yao Xue Xue Bao; 2002 Oct; 37(10):812-7. PubMed ID: 12567868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of halidor on experimental bronchospasm].
    Zhaugasheva SK
    Farmakol Toksikol; 1976; 39(1):50-3. PubMed ID: 943319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of infrared spectrophotometry to detect mixtures of halidor and baralgin in the internal organs of a cadaver].
    Makarenko TF; Voronova NV
    Sud Med Ekspert; 1985; 28(3):55-6. PubMed ID: 4071596
    [No Abstract]   [Full Text] [Related]  

  • 16. [Conditions for applying enteric coatings based on Eudragit L 30 D].
    Dechesne JP; Delporte JP; Jaminet F; Venturas K
    J Pharm Belg; 1982; 37(4):273-82. PubMed ID: 7143200
    [No Abstract]   [Full Text] [Related]  

  • 17. [Study of the absorption and excretion of Halidor by radioactive method].
    Nagy J; Blaskó K
    Orv Hetil; 1968 May; 109(21):Suppl:18-21. PubMed ID: 5720714
    [No Abstract]   [Full Text] [Related]  

  • 18. The influence of Eudragit type on the dissolution rate of acetylsalicylic acid from matrix tablets.
    Jovanović M; Jovicić G; Djurić Z; Agbaba D; Karljiković-Rajić K; Nikolić L; Radovanović J
    Acta Pharm Hung; 1997 Nov; 67(6):229-34. PubMed ID: 9423294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on absorption and excretion of bencyclane after acute and chronic administration].
    Faragò E; Simon J
    Arzneimittelforschung; 1970 Oct; 20(10):Suppl 10a:1380+. PubMed ID: 5536647
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
    Sauer D; Zheng W; Coots LB; McGinity JW
    Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.